Weill Cornell GI Oncology Program

Call Directions Website

Weill Cornell GI Oncology Program Enabling patients across the entire spectrum of cancers of the digestive system to have the highest quality care and treatment.

As New York’s premier healthcare network, Weill Cornell Medicine is at the forefront of scientific research and clinical trials. The Gastrointestinal (GI) Oncology Program provides access to state-of-the-art treatments, offering patients the opportunity to receive treatments not available elsewhere. Our physicians, ranging from our medical oncologists, world-class surgical oncologists, gastroenterologists and radiation oncologists, use the approach of precision medicine, which provides individualized cancer treatment based on specific genetic vulnerabilities of each patient’s tumor. Gastrointestinal cancers include:

• Esophagus and gastro-esophageal cancers
• Pancreatic cancers
• Stomach (Gastric) cancers
• Colon cancers
• Re**al and a**l cancers
• Liver cancers
• Neuroendocrine cancers
• Gallbladder cancers
• Cancers of the small intestine
• Sarcomas, including GIST

Our page aims to provide you with the latest information and research developments.

has historically been one of the most difficult cancers to diagnose and treat, but progress is being made. Find out mo...
10/06/2026

has historically been one of the most difficult cancers to diagnose and treat, but progress is being made. Find out more about recent treatment advances and what to know about KRAS, a protein mutated in over 90% of pancreatic cancers

Pancreatic cancer has been one of the most difficult cancers to diagnose and treat. However, important progress is being made to treat pancreatic cancer as researchers and oncologists are now able to target one of the most common drivers of the disease: a gene called KRAS.

Dr. Manish Shah weighed in on recent that found those who consumed a sugar-sweetened drink daily had a higher risk of ...
09/25/2026

Dr. Manish Shah weighed in on recent that found those who consumed a sugar-sweetened drink daily had a higher risk of developing . Learn more via Newsweek:

Regularly consuming sugar-sweetened beverages could more than double a person's risk of developing gastric cancer, a study has found.

Members of our Gastrointestinal (GI) Program team attended the Dava Oncology conference in Bermuda, where they spent...
09/24/2026

Members of our Gastrointestinal (GI) Program team attended the Dava Oncology conference in Bermuda, where they spent four days learning about the latest advances in GI oncology!

ICYMI: Daraxonrasib (Rasonque) was recently approved by the U.S. Food and Drug Administration for patients with metastat...
09/22/2026

ICYMI: Daraxonrasib (Rasonque) was recently approved by the U.S. Food and Drug Administration for patients with metastatic . Learn more about this new oral RAS-targeted therapy via Dr. Manish Shah:

Pancreatic cancer has been one of the most difficult cancers to diagnose and treat. However, important progress is being made to treat pancreatic cancer as researchers and oncologists are now able to target one of the most common drivers of the disease: a gene called KRAS.

07/09/2026

Congratulations to Dr. Despina Siolas for her recent Project Purple Research Recovery Grant in support of . Learn more about the grant and her research: https://bit.ly/4pc7ksx

Join Dr. Allyson Ocean for a Let's Win Pancreatic Cancer webinar on 7/8 to learn more about daraxonrasib and other new &...
07/02/2026

Join Dr. Allyson Ocean for a Let's Win Pancreatic Cancer webinar on 7/8 to learn more about daraxonrasib and other new & upcoming treatments, including those in . Register here: https://bit.ly/4xY0vig

WATCH: Dr. Manish Shah recaps the most exciting and practice changing gastrointestinal (GI) studies shared at with...
06/29/2026

WATCH: Dr. Manish Shah recaps the most exciting and practice changing gastrointestinal (GI) studies shared at with Medscape.

Breakthroughs in pancreatic cancer, novel drug combinations, and the role of observation in colorectal cancer are among the advances in gastrointestinal cancer at ASCO 2026 selected by Dr Manish Shah.

Dr. Despina Siolas spoke to PBS NewsHour about promising presented at the plenary session evaluating a new pill-ba...
06/03/2026

Dr. Despina Siolas spoke to PBS NewsHour about promising presented at the plenary session evaluating a new pill-based therapy for this difficult to treat disease:

The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.

Third-year fellow Dr. Jonathan Lee shares additional details on with Dr. Manish Shah that was shared at . Learn more ...
06/02/2026

Third-year fellow Dr. Jonathan Lee shares additional details on with Dr. Manish Shah that was shared at . Learn more about the Weill Cornell Medicine experience with liver transplantation for metastatic in the liver: https://bit.ly/4nQd1eW

Dr. Manish Shah explains insights from Weill Cornell Medicine research shared at on liver transplantation for metastat...
06/01/2026

Dr. Manish Shah explains insights from Weill Cornell Medicine research shared at on liver transplantation for metastatic : https://bit.ly/4wSG5Xh

Address

1305 York Avenue
New York, NY
10021

Telephone

(646) 962-6200

Website

Alerts

Be the first to know and let us send you an email when Weill Cornell GI Oncology Program posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Sponsored

Share

Category